Skip to content
Business Times – Lifestyle
Author:
Apollomics Inc.
Apollomics Announces $10 Million Private Placement Transaction
August 11, 2026
Apollomics Regains Full Compliance with Nasdaq Listing Requirements
July 13, 2026
Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia
June 24, 2026
Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress
April 27, 2026
Apollomics Inc. Announces $2.0 Million Bridge Financing
April 1, 2026